A recent JAMA Dermatology study compared biologics, phototherapy, and a step-therapy approach for treating psoriasis, focusing on their effectiveness, costs, and impact on quality of life. Published in February 2026, it provides fresh economic insights into these options.
Study Purpose
Researchers aimed to evaluate how well different psoriasis treatments work while weighing their costs and benefits to patients’ daily lives. They analyzed data on biologics (injected drugs like TNF inhibitors), narrowband UVB phototherapy (light therapy sessions), and a step-therapy plan starting with cheaper options before escalating. The goal was to identify the most cost-effective strategies amid rising biologic use.
Key Findings
Biologics reduced Psoriasis Area and Severity Index (PASI) scores by 91.6% on average, phototherapy by 71.1%, and step-therapy by 95.2%. Despite strong efficacy, phototherapy and step-therapy proved more cost-effective, offering substantial quality-of-life gains at lower expense than biologics alone. This suggests starting with non-drug options like light therapy can deliver solid results without the high price tag of ongoing injections.
What Patients Should Know
Think of this study as a “value report card” for psoriasis treatments—phototherapy gets high marks for clearing skin effectively while being easier on your wallet and lifestyle. It doesn’t mean biologics are bad; they’re powerful for severe cases, but trying light therapy first (often 2-3 sessions weekly) could save money and avoid needles. Always talk with your dermatologist, as individual skin type, location, and severity matter. In addition, home units make it convenient, matching office results in other trials.
Unlike biologics, which can raise infection risks, require lab monitoring, and carry rare long-term concerns, UVB phototherapy’s main side effects are mild redness or itching, like a sunburn that fades quickly. No systemic immune suppression means fewer worries about getting sick, making it safer for many, including kids and pregnant patients. This safety edge, paired with lower costs, positions it as a smart first choice.
Implications for Cytokind
Cytokind’s home-based narrowband UVB phototherapy devices align perfectly with this research, offering an affordable, effective alternative backed by economic evidence. As psoriasis affects millions, this validates expanding light therapy beyond clinics, supporting Cytokind’s mission to provide accessible relief from autoimmune and skin inflammation. It strengthens the case for prescribing Cytokind units early, potentially reducing long-term reliance on biologics.
